Wells Fargo analyst Chris Carey lowered the firm’s price target on Clorox to $135 from $140 and keeps an Underweight rating on the shares. The firm says Clorox is finding it harder to find solid footing in yet another “post-recovery reality” with a delayed return to shelf post-cyber, more trade promo to counter competitive activity, and in general less certainty on sales/margins.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Clorox price target lowered to $150 from $155 at Citi
- Clorox reports Q3 gross margin up 40 bps to 42.2% from 41.8% last year
- Clorox Releases Insightful Supplemental Financial Data
- Clorox Reports Q3 Fiscal Year 2024 Results, Updates Outlook
- Clorox raises FY24 adjusted EPS view to $5.80-$5.95 from $5.30-$5.50